SBI Securities 13F: Adds $1.4M to Moderna (MRNA) Stake
Key Points
- SBI Securities grew its Moderna, Inc. MRNA stake by 44.2% to 23,692 shares valued at about $4.56 million in a Form 13F filing on October 22, 2026.
- Other major institutional investors adjusted their positions, with Baillie Gifford & Co lowering its holdings by 1,778,708 shares to end with 18,206,778 shares worth $3.69 billion.
- Moderna shares recently traded around $202.62, sitting above their 50-day moving average as the biotechnology firm prepares for its next earnings release on November 6, 2026.
Get Moderna text alerts
We text you when insiders, Congress, analysts or big funds move on $MRNA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Moderna, Inc. alert may contain errors. Disclosures
SBI Securities increased its holdings in Moderna, Inc. MRNA by 7,267 shares during the quarter, bringing its total stake to 23,692 shares worth $4.56 million in an October 22, 2026 filing. The disclosures arrive via the firm's latest Form 13F submission filed with the Securities and Exchange Commission.
MRNA
Moderna, Inc.
SBI Securities vs. the S&P 500
Hypothetical returns from SBI Securities's disclosed trades, not real profit or advice. How we model this.
What Changed in SBI Securities's Moderna Position
The firm lifted its position by a 44.2% margin during the period. Prior to the adjustment, the firm held 16,425 shares of the biotechnology company. The final stake of 23,692 shares carried a reported value of $4,562,368.
Other Institutional Activity in Moderna
Other major institutional investors adjusted their positions in the biotechnology company during the same period. Baillie Gifford & Co grew its holdings by -1,778,708 shares, ending with 18,206,778 shares worth about $3,689,239,515 after an 8.9% reduction. Theleme Partners LLP grew its holdings by 9,657 shares, ending with 8,057,571 shares worth about $1,632,705,651 after a 0.1% increase.
Moderna, Inc. Stock Down 16.3%
Moderna closed at $202.63 on October 22, 2026, and recently traded around $202.62. The shares sit well above their 50-day moving average of $165.64 and their 200-day moving average of $80.51. The stock has traded between a 52-week low of $22.28 and a 52-week high of $254.48.
Recent Earnings
Moderna reported $2.23 billion in trailing-twelve-month revenue alongside trailing earnings of -$7.98 per share. The company posted a net profit margin of -141.4% and a return on equity of -39.0%. The company's next earnings report is scheduled for November 6, 2026.
Insider Buying and Selling at Moderna, Inc.
Chief Executive Officer Stephane J Bancel disposed of 499,246 shares on August 5, 2026, valued at $28,715,011. Officer Shannon Thyme Klinger sold 3,471 shares at an average price of $139.95 for a total value of $485,766 on September 1, 2026. Chief Financial Officer James M Mock parted with 34,836 shares at an average price of $134.49 worth $4,685,094 on September 10, 2026. President Stephen Hoge sold 80,575 shares valued at $11,691,420 on September 15, 2026.
Analysts Set New Price Targets
Rothschild & Co lowered its rating on the stock to a Sell with an $81.0 price target, moving from a prior target of $40.0 on September 3, 2026. Citigroup downgraded the stock to a Sell with an $80.0 price target, moving from $60.0 on September 30, 2026. Morgan Stanley maintained an Equal-Weight rating on the stock with a $95.0 price target on October 7, 2026. Goldman Sachs kept a Neutral rating and lifted its target to $137.0 on October 15, 2026. TD Cowen maintained a Hold rating and raised its target to $90.0 on October 21, 2026. Wall Street firms maintain a consensus hold rating and a mean price target of $127.16 across 19 analyst opinions.
About Moderna
Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that develops messenger RNA medicines for various diseases. The firm employs 4,700 people and focuses on infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions.
Bottom Line
Investors will watch the upcoming earnings release on November 6, 2026, for updates on revenue growth and pipeline progress. Subsequent Form 13F filings will reveal whether institutional interest continues to evolve.
Related Filing Alerts
Source: SBI Securities's 13F filing on $MRNA (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts